James F. Young Joins 3-V Biosciences Board of Directors
MENLO PARK, Calif., July 20 /PRNewswire/ -- 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors.
"We are very pleased to welcome Jim Young to the 3-V Board," said David M. Mott, 3-V's Executive Chairman. "Jim's expertise as a virologist, immunologist, drug developer and company builder make him extraordinarily well suited to assist 3-V in its mission to build the leading host cell factor anti-infective company. Jim has a great nose for science and the experience and wisdom in drug development gained from having been head of R&D at MedImmune for 19 years, from its founding until 2008 following its sale to AstraZeneca for $15.6 billion. Uniquely suited to 3-V's initial focus, Jim has particular expertise in discovering, developing and commercializing products targeting viruses including influenza, respiratory syncytial virus, human papillomavirus, and cytomegalovirus."
Most recently, Dr. Young graduated first in his class with a Certificate de Cuisine from Le Cordon Bleu Academie d'Art Culinaire de Paris in Paris, France. He currently serves on the Board of Directors of Novavax, Inc. and on the Board of Trustees of The Phillips Collection Museum of Modern Art in Washington, D.C. Previously, Dr. Young was with MedImmune, Inc. from 1988 through 2008 following its sale to AstraZeneca PLC. During his entire tenure, Dr. Young led MedImmune's research and development organization and was directly involved in the development of approximately twenty clinical programs and commercialization of Synagis® , RespiGam®, CytoGam®, Flumist®, and Ethyol®. At the time of his retirement from MedImmune, Dr. Young oversaw R&D functions including approximately 1,500 people and an annual budget in excess of $600 million. Prior to MedImmune, Dr. Young was a Director in the Department of Molecular Genetics at Smith Kline and French Laboratories. Dr. Young has served on the Boards of Directors of Xencor, Inc., Iomai, Inc. and Arriva Pharmaceuticals, Inc. He received his Ph.D. in Microbiology and Immunology from Baylor College of Medicine.
Synagis®, RespiGam®, CytoGam®, Flumist®, and Ethyol® are registered trademarks of MedImmune, LLC, an AstraZeneca PLC company.
About 3-V Biosciences
3-V Biosciences, Inc. is privately-held biopharmaceutical company dedicated to discovering and developing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches. The Company is located in Menlo Park, California and is backed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.
In addition to Dr. Young, 3-V's Board of Directors includes Ari Helenius, Ph.D., of the ETH Zurich, Gordon Ringold, Ph.D. of University of California Santa Cruz, Richard Klausner, M.D. of The Column Group, Beth Seideberg, M.D. of Kleiner Perkins Caulfield & Byers, and Robert Garland, M.D. and David Mott from New Enterprise Associates.
For additional information on 3-V Biosciences, please visit www.3vbio.com.
Stephen R. Brady
Vice President, Corporate Development, Strategy & Operations
SOURCE 3-V Biosciences, Inc.